MEMPHASYS LIMITED. — Capital/Financing Update 2017

Jul 2, 2017

ASX Release

==> picture [221 x 64] intentionally omitted <==

EXTENSION OF DIRECTOR LINE OF CREDIT

Sydney, Monday 3 July 2017

Memphasys (ASX: MEM) reports that the $200,000 line of credit facility announced on 23 February 2017 provided by Executive Director, Alison Coutts, under arms’ length terms to the Company has now been fully drawn down. Ms Coutts has agreed to extend the line of credit by a further $200,000. The line of credit is to be drawn upon, if required, to supplement funds that will be provided through other capital raising activities and will be used for working capital purposes.

The Company will apply for a waiver under Listing Rule 10.1 to enable the line of credit to be secured.

Details of the extended line of credit are as follows:

Credit facility: $400,000 Interest rate: 10% per annum, payable at the end of the term Term: 1 year term expiring 23 February 2018

Redemption: the loan funds provided under the facility and accrued interest may be repaid by the Company at its discretion at any time before the expiry of the facility

For further information please contact:

Alison Coutts Executive Chairman +61 2 8415 7300 alison.coutts@memphasys.com

About Memphasys

Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.

Postal Address Contact Details E info@memphasys.com P.O. Box 2202 P +612 8415 7300 W memphasys.com Homebush West NSW 2140 F +612 8415 7399 ABN 33 120 047 556

Memphasys Limited 30-32 Richmond Road Homebush West NSW 2140